Zapping kidney nerves may tame both hypertension and anxiety

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Consecutive patients aged 30-70 years with arterial hypertension diagnosed at least 3 months prior to the inclusion. * Office blood pressure (OBP) \>140/90mmHg and \<160/100 mmHg * Either no baseline hypertension treatment or hypertension treatment with one drug. The antihypertensive treatment will include a renin-angiotensin system (RAS) blocker \[either an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB)\] or a calcium channel blocker (CCB). * Unchanged antihypertensive therapy during the prior 8 weeks. * Patients with baseline anxiety subscore ≥ 8 according to the Hospital Anxiety and Depression Scale (HADS) Exclusion Criteria: * Patients with secondary arterial hypertension or under treatment with b-blockers, diuretics, mineralocorticoid receptors antagonists (MRAs) or a centrally acting alpha-adrenergic agonist. * Patients under treatment with antidepressants and/or anxiolytic drugs. * Patients with a glomerular filtration rate (eGFR)\] \<45 ml / min / 1.73 m2 calculated using the CKD-EPI formula15. * Patients with evidence of any of the following criteria on either renal artery side: * Main renal artery diameter \< 3.0 mm or \> 8 mm * Main renal treatable artery length \< 20 mm * Presence of renal artery stenosis of any origin ≥ 30% * Accessory arteries with diameter ≥ 2mm \<3.0 mm * Calcification in renal arteries at location where energy is to be delivered * A single functioning kidney * Prior renal denervation procedure * Presence of abnormal kidney tumors * Renal artery with aneurysm * Pre-existing renal stent or history of renal artery angioplasty * Pre-existing aortic stent or history of aortic aneurysm * Fibromuscular disease of the renal arteries * Iliac/femoral artery stenosis precluding insertion of the Paradise Catheter * Patients with a history of acute coronary syndrome or stroke during the previous six months or Scheduled coronary interventional therapy during the next six months. * Patients with permanent atrial fibrillation, chronic heart failure and NYHA functional status II-IV, Cancer under therapy (radiotherapy, chemotherapy, immunotherapy) * Patients with life expectancy \<1 year (at the time of inclusion). * Pregnant women or women who are planning to become pregnant. * Patients who do not provide written consent to participate in the study